Charles J Ryan1, Thian Kheoh2, Jinhui Li3, Arturo Molina4, Peter De Porre5, Joan Carles6, Eleni Efstathiou7, Philip W Kantoff8, Peter F A Mulders9, Fred Saad10, Kim N Chi11. 1. Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA. Electronic address: ryanc@medicine.ucsf.edu. 2. Janssen Research & Development, San Diego, CA. 3. Johnson & Johnson Medical China, Shanghai, China. 4. Janssen Research & Development, Menlo Park, CA. 5. Janssen Research & Development, Beerse, Belgium. 6. Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain. 7. The University of Texas MD Anderson Cancer Center, Houston, TX. 8. Memorial Sloan Kettering Cancer Center, New York, NY. 9. Radboud University Medical Centre, Nijmegen, The Netherlands. 10. Centre Hospitalier de l'Université de Montréal/CRCHUM, Montréal, QC, Canada. 11. BC Cancer Agency, Vancouver, BC, Canada.
Abstract
BACKGROUND: Radiographic progression-free survival (rPFS) is associated with overall survival (OS) in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients. Using readily assessable baseline clinical and laboratory parameters, we developed a prognostic index model for rPFS in chemotherapy-naïve mCRPC patients without visceral disease who were treated with abiraterone acetate plus prednisone. METHODS: Data from the abiraterone acetate plus prednisone arm of COU-AA-302 were used. rPFS was defined based on modified Prostate Cancer Working Group 2 criteria. Baseline variables were assessed for association with rPFS through univariate Cox modeling. The lower (LLN) and upper (ULN) limits of laboratory normal were used to dichotomize most laboratory parameters; baseline median was used to dichotomize prostate-specific antigen (PSA). Prognostic factors for rPFS were identified by multivariate Cox modeling. Model accuracy was estimated by the C-index. RESULTS: Presence of lymph node metastasis (hazard ratio [HR] = 1.76, P < .0001), lactate dehydrogenase > ULN (234 IU/L) (HR = 1.71, P = .0001), ≥ 10 bone metastases (HR = 1.71, P = .0015), hemoglobin ≤ LLN (12.7 g/dL) (HR = 1.47, P = .0030) and PSA > 39.5 ng/mL (HR = 1.42, P = .0078) were associated with poor outcome. Patients were categorized into 3 prognostic groups (good, n = 230; intermediate, n = 152; poor, n = 164) based on number of risk factors. Median rPFS was calculated (27.6, 16.6, and 8.3 months for good, intermediate, and poor, respectively). The C-index was 0.83 (95% confidence interval = 0.73-0.91). CONCLUSIONS: The prognostic index model for rPFS reveals differential outcomes based on factors readily available in clinical practice. If validated, this model can be integrated into clinical practice and design of risk-stratified trials.
BACKGROUND: Radiographic progression-free survival (rPFS) is associated with overall survival (OS) in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients. Using readily assessable baseline clinical and laboratory parameters, we developed a prognostic index model for rPFS in chemotherapy-naïve mCRPC patients without visceral disease who were treated with abiraterone acetate plus prednisone. METHODS: Data from the abiraterone acetate plus prednisone arm of COU-AA-302 were used. rPFS was defined based on modified Prostate Cancer Working Group 2 criteria. Baseline variables were assessed for association with rPFS through univariate Cox modeling. The lower (LLN) and upper (ULN) limits of laboratory normal were used to dichotomize most laboratory parameters; baseline median was used to dichotomize prostate-specific antigen (PSA). Prognostic factors for rPFS were identified by multivariate Cox modeling. Model accuracy was estimated by the C-index. RESULTS: Presence of lymph node metastasis (hazard ratio [HR] = 1.76, P < .0001), lactate dehydrogenase > ULN (234 IU/L) (HR = 1.71, P = .0001), ≥ 10 bone metastases (HR = 1.71, P = .0015), hemoglobin ≤ LLN (12.7 g/dL) (HR = 1.47, P = .0030) and PSA > 39.5 ng/mL (HR = 1.42, P = .0078) were associated with poor outcome. Patients were categorized into 3 prognostic groups (good, n = 230; intermediate, n = 152; poor, n = 164) based on number of risk factors. Median rPFS was calculated (27.6, 16.6, and 8.3 months for good, intermediate, and poor, respectively). The C-index was 0.83 (95% confidence interval = 0.73-0.91). CONCLUSIONS: The prognostic index model for rPFS reveals differential outcomes based on factors readily available in clinical practice. If validated, this model can be integrated into clinical practice and design of risk-stratified trials.
Authors: Karim Fizazi; Howard I Scher; Arturo Molina; Christopher J Logothetis; Kim N Chi; Robert J Jones; John N Staffurth; Scott North; Nicholas J Vogelzang; Fred Saad; Paul Mainwaring; Stephen Harland; Oscar B Goodman; Cora N Sternberg; Jin Hui Li; Thian Kheoh; Christopher M Haqq; Johann S de Bono Journal: Lancet Oncol Date: 2012-09-18 Impact factor: 41.316
Authors: Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor Journal: Lancet Date: 2010-10-02 Impact factor: 79.321
Authors: Arun A Azad; Stanislav V Volik; Alexander W Wyatt; Anne Haegert; Stephane Le Bihan; Robert H Bell; Shawn A Anderson; Brian McConeghy; Robert Shukin; Jenny Bazov; Jack Youngren; Pamela Paris; George Thomas; Eric J Small; Yuzhuo Wang; Martin E Gleave; Colin C Collins; Kim N Chi Journal: Clin Cancer Res Date: 2015-02-23 Impact factor: 12.531
Authors: Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf Journal: N Engl J Med Date: 2012-12-10 Impact factor: 91.245
Authors: Oren Smaletz; Howard I Scher; Eric J Small; David A Verbel; Alex McMillan; Kevin Regan; W Kevin Kelly; Michael W Kattan Journal: J Clin Oncol Date: 2002-10-01 Impact factor: 44.544
Authors: Susan Halabi; Chen-Yen Lin; Eric J Small; Andrew J Armstrong; Ellen B Kaplan; Daniel Petrylak; Cora N Sternberg; Liji Shen; Stephane Oudard; Johann de Bono; Oliver Sartor Journal: J Natl Cancer Inst Date: 2013-10-17 Impact factor: 13.506
Authors: Emmy Boerrigter; Guillemette E Benoist; Joanneke K Overbeek; Rogier Donders; Niven Mehra; Inge M van Oort; Rob Ter Heine; Nielka P van Erp Journal: Br J Clin Pharmacol Date: 2021-10-08 Impact factor: 3.716
Authors: Charles J Ryan; E David Crawford; Neal D Shore; Willie Underwood; Mary-Ellen Taplin; Anil Londhe; Peter St John Francis; Jennifer Phillips; Tracy McGowan; Philip W Kantoff Journal: J Urol Date: 2018-04-06 Impact factor: 7.450
Authors: A J Armstrong; P Lin; C S Higano; C N Sternberg; G Sonpavde; B Tombal; A J Templeton; K Fizazi; D Phung; E K Wong; A Krivoshik; T M Beer Journal: Ann Oncol Date: 2018-11-01 Impact factor: 32.976
Authors: Martin Boegemann; Katrin Schlack; Lena Früchtenicht; Julie Steinestel; Andres Jan Schrader; Yvonne Wennmann; Laura-Maria Krabbe; Okyaz Eminaga Journal: Oncotarget Date: 2019-08-20
Authors: Renata Poteska; Kambiz Rahbar; Axel Semjonow; Andres Jan Schrader; Martin Boegemann; Katrin Schlack Journal: BMC Cancer Date: 2022-04-08 Impact factor: 4.430
Authors: Emmy Boerrigter; Guillemette E Benoist; Inge M van Oort; Gerald W Verhaegh; Anton F J de Haan; Onno van Hooij; Levi Groen; Frank Smit; Irma M Oving; Pieter de Mol; Tineke J Smilde; Diederik M Somford; Paul Hamberg; Vincent O Dezentjé; Niven Mehra; Nielka P van Erp; Jack A Schalken Journal: Cancers (Basel) Date: 2021-12-14 Impact factor: 6.639
Authors: Emmy Boerrigter; Guillemette E Benoist; Inge M van Oort; Gerald W Verhaegh; Onno van Hooij; Levi Groen; Frank Smit; Irma M Oving; Pieter de Mol; Tineke J Smilde; Diederik M Somford; Niven Mehra; Jack A Schalken; Nielka P van Erp Journal: Mol Oncol Date: 2021-05-29 Impact factor: 6.603